Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBL-514 in Edematous Fibrosclerotic Panniculopathy (EFP) Cellulite
NCT05632926Phase 2Completed
- Sponsor
- Caliway Biopharmaceuticals
- Start
- Jan 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of CBL-514 in cellulite (3 arms), sponsored by Caliway Biopharmaceuticals. Primary endpoint: Cellulite Severity Scale at 4 weeks. Started Jan 2023; status: completed.
02
Drugs
CBL-514
03
Conditions
cellulite
Beyond the preview
Go deeper on NCT05632926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05632926.